An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interaction Between Tegoprazan and Novel Oral Anticoagulants (NOACs) After Multiple Oral Dosing in Healthy Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 87
- 试验地点
- 1
- 主要终点
- AUCτ and Css,max of edoxaban
研究概览
简要总结
This study aims to evaluate the effects of combination therapy of tegoprazan and novel oral anticoagulants (NOACs) on the pharmacokinetic and pharmacodynamic properties of NOACs in healthy adults.
详细描述
A randomized, open-label, multiple-dose, two-arm, two-period crossover study
[Cohort 1] To evaluate the effects of combination therapy of tegoprazan and edoxaban on the pharmacokinetic and pharmacodynamic properties of edoxaban in healthy adults.
[Cohort 2] To evaluate the effects of combination therapy of tegoprazan and apixaban on the pharmacokinetic and pharmacodynamic properties of apixaban in healthy adults.
[Cohort 3] To evaluate the effects of combination therapy of tegoprazan and rivaroxaban on the pharmacokinetic and pharmacodynamic properties of rivaroxaban in healthy adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 54 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults aged ≥ 19 years to < 55 years at the time of screening
- •Those with body weight ≥ 45 kg (but ≥ 60 kg for cohort 1 and cohort 2) and body mass index (BMI) in the range of 19.0 kg/m2 to 27.0 kg/m2 at the time of screening
- •☞ BMI = weight (kg) / height (m)2
- •Those who have neither congenital/chronic disease (within recent 3 years) nor pathological symptoms/findings as a result of medical examination
- •Those determined to be eligible for this study based on the findings of screening such as clinical laboratory tests (hematological test, blood chemistry test, blood coagulation test, urinalysis, test for viruses/bacteria, etc.), vital signs, and electrocardiogram (ECG) which are performed by the investigator according to the properties of medicines
- •Those who are fully informed of study purpose, procedures, etc., voluntarily decide to participate in this study, and sign an informed consent form (ICF) approved by the Institutional Review Board (IRB) of Jeonbuk National University Hospital, prior to participation in the study
- •Those with a capability/willingness to participate throughout the study
排除标准
- •Medical history of clinically significant blood, renal, endocrine, respiratory, gastrointestinal (peptic ulcer, etc.), urinary, cardiovascular, hepatic, psychiatric, neurological or immune disease (but except for history of simple dental treatment such as tartar, impacted teeth, and third molar teeth) or evidence thereof
- •Previous history of gastrointestinal disease (except for esophageal disease such as esophageal achalasia or esophageal stricture, inflammatory bowel disease (Crohn's disease, ulcerative colitis)) or surgery (not including simple appendectomy, hernia surgery, tooth extraction, etc.) which may affect drug absorption
- •Following findings of clinical laboratory tests:
- •☞ ALT or AST value > twice the upper limit of normal (ULN)
- •History of periodic alcohol consumption exceeding 210 g/week within 6 months prior to screening (beer (5%) 1 glass (250 mL) = 10 g, soju (20%) 1 glass (50 mL) = 8 g, wine (12%) 1 glass (125 mL) = 12 g)
- •Administration of another investigational product within 6 months prior to the first dose of the investigational product
- •History of serious alcohol or drug misuse and abuse within 1 year prior to screening
- •Administration of drugs known to markedly induce or inhibit drug metabolizing enzymes within 30 days prior to the first dose of the investigational product
- •History of smoked cigarettes ≥ 20 cigarettes/day within 6 months prior to screening
- •Administration of a prescription or non-prescription drug within 10 days prior to the first dose of the investigational product
- •Whole blood donation within 2 months prior to the first dose of the investigational product or apheresis donation within 1 month prior to the first dose of the investigational product
- •Those who may be put at an increased risk due to the adminisration of the investigational product and study participation or have a severe acute/chronic medical or mental condition which may interfere with the interpretation of study results
- •Patients with hypersensitivity to tegoprazan, edoxaban, apixaban, rivaroxaban, etc. (e.g., asthma, acute rhinitis, nasal polyp, angioedema, urticaria, allergic reactions, etc.)
- •Patients with a clinically significant bleeding
- •Patients with hemostatic disorder and hepatic disease related to a clinically significant risk of bleeding
- •Severe hepatic impairment
- •Renal impairment (eGFR <60 ml/min/1.73m2)
- •Hereditary problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •Pregnant/breast-feeding women
- •Those who cannot use medically acceptable contraceptive methods throughout the study
- •▶ Medically acceptable contraceptive methods
- •Use of intrauterine device (IUD) showing a demonstrated pregnancy failure rate
- •Combined use of barrier contraceptive method (for male or female) and spermicide
- •Use of vasectomy, tubectomy/tubal ligation, or hysterectomy
- •Those who are not eligible for the study in the judgment of the investigator
研究组 & 干预措施
Edoxaban 60mg
Multiple dosing of edoxaban alone once daily for 5 days
干预措施: Edoxaban 60mg (Drug)
Edoxaban 60mg + Tegoprazan 50mg
Multiple dosing of edoxaban once daily in combination with tegoprazan once daily for 5 days
干预措施: Tegoprazan 50mg (Drug)
Edoxaban 60mg + Tegoprazan 50mg
Multiple dosing of edoxaban once daily in combination with tegoprazan once daily for 5 days
干预措施: Edoxaban 60mg (Drug)
Apixaban 5mg
Multiple dosing of apixaban alone twice daily for 5 days
干预措施: Apixaban 5mg (Drug)
Apixaban 5mg + Tegoprazan 50mg
Multiple dosing of apixaban twice daily in combination with tegoprazan once daily for 5 days
干预措施: Tegoprazan 50mg (Drug)
Apixaban 5mg + Tegoprazan 50mg
Multiple dosing of apixaban twice daily in combination with tegoprazan once daily for 5 days
干预措施: Apixaban 5mg (Drug)
Rivaroxaban 20mg
Multiple dosing of rivaroxaban alone once daily for 5 days
干预措施: Rivaroxaban 20mg (Drug)
Rivaroxaban 20mg + Tegoprazan 50mg
Multiple dosing of rivaroxaban once daily in combination with tegoprazan once daily for 5 days
干预措施: Tegoprazan 50mg (Drug)
Rivaroxaban 20mg + Tegoprazan 50mg
Multiple dosing of rivaroxaban once daily in combination with tegoprazan once daily for 5 days
干预措施: Rivaroxaban 20mg (Drug)
结局指标
主要结局
AUCτ and Css,max of edoxaban
时间窗: Pre-dose(0 hour) on 1D, 3D, and 4D for each period; pre-dose(0 hour) up to 48 hours after treatment on 5D for each period
Area under the plasma concentration-time curve during a steady-state dosing interval (τ) and maximum plasma concentration at steady state of edoxaban
AUCτ and Css,max of apixaban
时间窗: Pre-dose (0 hour) in the morning on 1D and in the morning and afternoon on 4D for each period; pre-dose(0 hour) in the morning up to 48 hours after treatment on 5D for each period
Area under the plasma concentration-time curve during a steady-state dosing interval (τ) and maximum plasma concentration at steady state of apixaban
AUCτ and Css,max of rivaroxaban
时间窗: Pre-dose (0 hour) on 1D, 3D, and 4D for each period; pre-dose(0 hour) up to 48 hours after treatment on 5D for each period
Area under the plasma concentration-time curve during a steady-state dosing interval (τ) and maximum plasma concentration at steady state of rivaroxaban
AUECτ and Emax of Anti-Factor Xa activity, PT, aPTT, and Prothrombin (INR)
时间窗: Pre-dose (0 hour) up to 24 hours after treatment on 5D for each period
Area under the effect-time curve over the dosing interval (τ) at steady state and maximum effect of Anti-Factor Xa activity, PT, aPTT, and Prothrombin (INR)
次要结局
未报告次要终点